Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621089 | 0.82 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL3602618 | 0.81 | CYP2D6 (0.41) | KCNH2CYP2D6SLC2A1 | |
| SCHEMBL3149928 | 0.75 | KCNH2 (0.40) | KCNH2SLC2A1 | |
| SCHEMBL3840641 | 0.71 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL3328622 | 0.68 | TSHR (0.34) | — | |
| SCHEMBL4429997 | 0.68 | KCNH2 (0.33) | KCNH2SLC2A1 | |
| SCHEMBL3841871 | 0.67 | TMEM97 (0.44) | KCNH2CYP2D6 | |
| SCHEMBL3149833 | 0.65 | KCNH2 (0.43) | KCNH2SLC2A1 | |
| SCHEMBL2821729 | 0.65 | KCNH2 (0.43) | KCNH2SLC2A1 | |
| SCHEMBL2821724 | 0.65 | KCNH2 (0.43) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2137195-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008128953-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | KCNH2 2914/4885CYP2D6 1687/4885SLC2A1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.